Skip to main content
Clinical Trials/JPRN-jRCTs011210015
JPRN-jRCTs011210015
Recruiting
Phase 1

An exploratory clinical study to evaluate the usefuleness of 5-aminolevulinic acid for pancreatobiliary malignant tumor

Tanaka Kimitaka0 sites15 target enrollmentJune 4, 2021

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Biliary cancer, pancreatic cancer
Sponsor
Tanaka Kimitaka
Enrollment
15
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 4, 2021
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Tanaka Kimitaka

Eligibility Criteria

Inclusion Criteria

  • (1\) over 20 years old
  • (2\) Patients who undergo surgery for malignant tumors in the biliary and pancreatic regions (limited to patients with malignant tumors confirmed by preoperative histological examination)
  • (3\) patients who has obtained written consent

Exclusion Criteria

  • (1\) Patients with contraindications to 5\-ALA: a. Patients with a history of hypersensitivity to porphyrin, b. Patients with porphyria, c. Patients recieving drugs or foods known to cause photosensitivity (tetracycline antibiotics, sulfonamides, new quinolones, hypericin or Hypericum perforatum (St. John's Wort)), d. a pregnant woman or a woman who may be pregnant
  • (2\) Patients with preoprative liver impairment of 1\.5 times or more than the normal value in the laboratory test.
  • (3\) Patients with preoperative renal impairment with an eGFR of less than 50 or patients on dialysis
  • (4\) Patients with a history of ischemic heart disease
  • (5\) Pregnant women, lactating women and female patients who wish to become pregnant
  • (6\) Patients with heart pacemaker or implantable cardiac defibrillator
  • (7\) Patients whom the principal resercher determined to be unsuitable for study

Outcomes

Primary Outcomes

Not specified

Similar Trials